MedTrace Logo

Convalescent Plasma for Patients With COVID-19

NCT04385199 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-05-02

Study results available
· View outcomes & findings →

Summary

Pilot study of tolerability and efficacy of transfusion of 200mL of convalescent plasma in patients with COVID-19 respiratory disease.

Conditions

  • Coronavirus Infection
  • Coronavirus
  • COVID

Interventions

BIOLOGICAL

Convalescent plasma

One 200mL transfusion of ABO compatible convalescent plasma over 3 hours

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Principal Investigators

  • Geneva Tatem, MD · Henry Ford Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-04
Primary Completion
2020-08-01
Completion
2020-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04385199 on ClinicalTrials.gov